Last reviewed · How we verify
NCT04284072: SeizeIT2
Clinical Scenarios for Long-term Monitoring of Epileptic Seizures With a Wearable Biopotential Technology
NA trial testing Sensor Dot in Epilepsy in 496 participants. Completed in 30 June 2022.
30 June 2022
Quick facts
| Lead sponsor | Universitaire Ziekenhuizen KU Leuven |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 496 |
| Start date | 22 June 2020 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 June 2022 |
| Sites | 7 locations across Belgium, Sweden, United Kingdom, Germany, Portugal |
Drugs / interventions tested
- Sensor Dot
Conditions studied
- Epilepsy — all drugs for Epilepsy →
Sponsor
Universitaire Ziekenhuizen KU Leuven — full company profile →
Who can join
4 and older, any sex, with Epilepsy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Clinically validate a biopotential and motion recording wearable device (Byteflies Sensor Dot) for detection of epileptic seizures in the epilepsy monitoring unit (EMU) and at home.
Publications & conference data
7 peer-reviewed publications reference this trial (live from Europe PMC):
-
Accurate detection of typical absence seizures in adults and children using a two-channel electroencephalographic wearable behind the ears.
Swinnen L, Chatzichristos C, Jansen K, Lagae L, et al · · 2021 · cited 57× · PMID 34490891 · DOI 10.1111/epi.17061 -
The power of ECG in multimodal patient-specific seizure monitoring: Added value to an EEG-based detector using limited channels.
Vandecasteele K, De Cooman T, Chatzichristos C, Cleeren E, et al · · 2021 · cited 38× · PMID 34240748 · DOI 10.1111/epi.16990 -
High precision in epileptic seizure self-reporting with an app diary.
Zabler N, Swinnen L, Biondi A, Novitskaya Y, et al · · 2024 · cited 10× · PMID 38982283 · DOI 10.1038/s41598-024-66932-y -
Classification with a Deferral Option and Low-Trust Filtering for Automated Seizure Detection.
Becker T, Vandecasteele K, Chatzichristos C, Van Paesschen W, et al · · 2021 · cited 10× · PMID 33557034 · DOI 10.3390/s21041046 -
SeizeIT2: Wearable Dataset Of Patients With Focal Epilepsy.
Bhagubai M, Chatzichristos C, Swinnen L, Macea J, et al · · 2025 · cited 2× · PMID 40664714 · DOI 10.1038/s41597-025-05580-x -
Automated Sleep Staging in Epilepsy Using Deep Learning on Standard Electroencephalogram and Wearable Data.
Macea J, Heremans ERM, Proost R, De Vos M, et al · · 2025 · cited 1× · PMID 40176726 · DOI 10.1111/jsr.70061 -
A multicenter, video-EEG-based validation of a multimodal wearable device for focal seizure detection in adults: The SeizeIT2 study.
Swinnen L, Bhagubai M, Chatzichristos C, Weber Y, et al · · 2026 · PMID 41949013 · DOI 10.1002/epi4.70260
Verify or expand the search:
- PubMed search for NCT04284072
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Epilepsy
Currently open trials in the same condition.
- NCT07095933 — The Safety and Efficacy Evaluation of Everolimus as an Adjunctive Treatment for Focal Refractory Epilepsy · EARLY_PHASE1 · recruiting
- NCT07224191 — Hippocampal Oscillations During Exploration · NA · recruiting
- NCT07219407 — A Long-term Study of the Safety and Effectiveness of RAP-219 in Adults With Focal Onset Seizures · Phase 2 · recruiting
- NCT07417280 — LIFUS For Neurological Disorders · NA · recruiting
- NCT07490769 — Levetiracetam Three Times Daily in Epilepsy · Phase 3 · recruiting
Other Universitaire Ziekenhuizen KU Leuven trials
Trials by the same sponsor.
- NCT06831955 — LifEStyle Intervention to Enhance Efficacy of Neoadjuvant Therapy in Patients With Triple Negative Breast Cancer · Phase 2 · recruiting
- NCT07356505 — Efficacy and Safety of Micra AV2 Transcatheter Pacing System · NA · recruiting
- NCT07286968 — Gastro-Intestinal Digestion and Physiology After Bariatric Surgery · recruiting
- NCT06962137 — Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer · Phase 2 · recruiting
- NCT07270536 — Accelerated Pacing and Cardiac Filling Pressures During Exercise in Patients With Heart Failure With Preserved Ejection · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04284072 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Universitaire Ziekenhuizen KU Leuven
- Last refreshed: 8 November 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04284072.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing